Singapore Markets close in 2 hrs 15 mins
Straits Times Index
3,131.15 -3.51 (-0.11%) Nikkei
28,860.62 +405.02 (+1.42%) Hang Seng
23,993.34 +9.68 (+0.04%) FTSE 100
7,339.90 +210.69 (+2.96%) BTC-USD
50,633.09 -550.08 (-1.07%) CMC Crypto 200
1,311.89 -129.87 (-9.01%)
SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 70.86 |
| Open | 63.90 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's range | 63.04 - 70.88 |
| 52-week range | 51.72 - 96.48 |
| Volume | |
| Avg. volume | 327,603 |
| Market cap | 3.423B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
DURHAM, N.C. & STAMFORD, Conn., June 28, 2021--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combination
© 2021 Yahoo. All rights reserved.
